- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03487692
Medical Care, Education, Social Support, And Goal-setting to Empower Self-management for Diabetes (MESSAGES)
1 november 2022 bijgewerkt door: University of Chicago
Diabetes MESSAGES (Medical Care, Education, Social Support, And Goal-setting to Empower Self-management): Implementing Diabetes Group Visits and Text Messaging in Community Health Centers
Diabetes group visits, shared appointments where patients receive self-management education in a group setting and have a medical visit, are a promising way to deliver high quality diabetes care.
Group visits can improve glycemic control and decrease healthcare utilization.
To date, no studies have systematically implemented a diabetes group visit intervention in a network of U.S. community health centers.
The University of Chicago is partnering with Midwest Clinicians' Network (MWCN), a member organization of 130 health centers across ten Midwestern states.
Approximately half of all Federally Qualified Health Centers in this region are affiliated with MWCN.
The objectives of the study are [1] providers and staff at 20 health centers will have the requisite knowledge, skills, and motivation to implement a diabetes group visit plus text messaging intervention at their sites; [2] changes in diabetes processes of care; knowledge, attitudes, and skills for diabetes self-management; clinical outcomes; and health care utilization for patients participating in the diabetes group visit program will be evaluated; and [3] the diabetes group visit program will be available for dissemination among and use by health centers and healthcare providers at the local, state, regional, and national levels.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
UChicago and MWCN will recruit and enroll 20 health centers (HCs) to participate in a training intervention and to implement diabetes group visit and text messaging programs at their clinic sites.
Each HC will assemble a team of 3-4 providers and staff to participate in the training.
HCs will be randomized to one of two training cohorts.
HC providers and staff will attend two in-person Learning Sessions in Chicago and a series of monthly webinars, recruit and enroll patients, implement a 6-month diabetes group visit and text messaging program plus subsequent booster sessions, complete periodic surveys and interviews, assist with data collection through patient surveys and chart abstraction, and present their program to peer HCs during Learning Sessions and to local stakeholders, state primary care organizations, or other professional groups.
Each HC will enroll 15 patients in the group visit and text messaging program; the 2018 Training Cohort will do so immediately following their enrollment in the study and the 2020 Training Cohort will do so after 18 months.
During the first 18 months, the 2020 Training Cohort will collect data from electronic health records (EHR) of randomly selected patients to serve as a control group.
Changes in self-reported outcomes, diabetes processes of care, and clinical outcomes will be assessed for intervention patients from baseline through 2 year follow up, and processes of care and clinical outcomes will be compared for intervention vs. control participants.
Capacity of HC providers and staff to conduct a group visit and text messaging intervention for patients with diabetes, as well as their confidence in identifying and addressing health disparities, will be evaluated through surveys and in-depth interviews.
This study will expand knowledge of the barriers, facilitators, and perceived benefits and drawbacks of group visit and text messaging interventions and inform the development of a toolkit that will be disseminated to other HCs.
Studietype
Ingrijpend
Inschrijving (Werkelijk)
265
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60637
- University of Chicago
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- 18 years or older
- diagnosis of type 2 diabetes
- attended at least two appointments at the HC within the past year, with at least one of them being during the past six months
- last documented A1c result greater than or equal to 8.0% (test must have been done during the last 6 months)
- own a cellular phone with text messaging capabilities
- have the ability to read and send text messages
- English or Spanish speaking
Exclusion Criteria:
- pregnant or planning to become pregnant
- uncontrolled psychiatric problem
- dementia or other cognitive impairment
- hearing difficulties or severe physical disability that would prevent them from participation in group visit
- planning to relocate in the next year or leave the area during the group visit period
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Onderzoek naar gezondheidsdiensten
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: 2018 Training Cohort
10 health centers will be randomized to the 2018 Training Cohort.
Teams from these health centers will be trained and will implement a 6 month diabetes group visit and text messaging intervention (Diabetes MESSAGES Program).
|
Health centers in the 2018 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient.
At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program.
Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
|
|
Ander: 2020 Training Cohort
10 health centers will be randomized to the 2020 Training Cohort.
Prior to beginning training, these health centers will collect data on randomly selected patients receiving usual care to serve as the control group.
After this first parallel group trial period, teams from these health centers will be trained and will implement the 6 month diabetes group visit and text messaging intervention during a second single group trial period (Diabetes MESSAGES Program (second trial)).
|
During the first trial period, health centers in the 2020 Training Cohort will collect data on patients receiving usual care.
After the first trial period, health centers in the 2020 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient.
At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program.
Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Hemoglobin A1C
Tijdsspanne: change from baseline to 12 months
|
change from baseline to 12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Hemoglobin A1C
Tijdsspanne: baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only
|
baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only
|
|
|
Blood pressure
Tijdsspanne: baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only
|
baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only
|
|
|
Weight
Tijdsspanne: baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only
|
baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only
|
|
|
Cholesterol
Tijdsspanne: baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only
|
baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only
|
|
|
Diabetes processes of care
Tijdsspanne: baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only
|
Receipt of recommended screenings, exams, referrals, and vaccinations
|
baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only
|
|
Medication management of diabetes
Tijdsspanne: baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only
|
changes in prescribed diabetes medications for patients with inadequate diabetes control
|
baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only
|
|
Number of hypoglycemic events
Tijdsspanne: baseline, 6 month, and 12 month for intervention patients only
|
baseline, 6 month, and 12 month for intervention patients only
|
|
|
Number of hospital admissions
Tijdsspanne: baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only
|
baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only
|
|
|
Number of primary care, specialist, and ER visits
Tijdsspanne: baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only
|
baseline, 6 month, and 18 month for intervention vs. control patients; 30 month for intervention patients only
|
|
|
Smoking status
Tijdsspanne: baseline, 6 month, and 12 month for intervention patients only
|
baseline, 6 month, and 12 month for intervention patients only
|
|
|
Health related quality of life (SF-12)
Tijdsspanne: baseline, 6 month, and 12 month for intervention patients only
|
baseline, 6 month, and 12 month for intervention patients only
|
|
|
Depression (PHQ-2)
Tijdsspanne: baseline, 6 month, and 12 month for intervention patients only
|
baseline, 6 month, and 12 month for intervention patients only
|
|
|
Summary of Diabetes Self-Care Activities Measure
Tijdsspanne: baseline, 6 month, and 12 month for intervention patients only
|
baseline, 6 month, and 12 month for intervention patients only
|
|
|
Understanding of Diabetes Self-Management (Diabetes Care Profile)
Tijdsspanne: baseline, 6 month, and 12 month for intervention patients only
|
baseline, 6 month, and 12 month for intervention patients only
|
|
|
Attitudes Towards Diabetes (Diabetes Care Profile)
Tijdsspanne: baseline, 6 month, and 12 month for intervention patients only
|
baseline, 6 month, and 12 month for intervention patients only
|
|
|
Diabetes Distress Scale (DDS-2)
Tijdsspanne: baseline, 6 month, and 12 month for intervention patients only
|
baseline, 6 month, and 12 month for intervention patients only
|
|
|
Diabetes Quality of Life Scale
Tijdsspanne: baseline, 6 month, and 12 month for intervention patients only
|
baseline, 6 month, and 12 month for intervention patients only
|
|
|
Diabetes Self-Empowerment Scale
Tijdsspanne: baseline, 6 month, and 12 month for intervention patients only
|
baseline, 6 month, and 12 month for intervention patients only
|
|
|
Diabetes Social Support Scale
Tijdsspanne: baseline, 6 month, and 12 month for intervention patients only
|
baseline, 6 month, and 12 month for intervention patients only
|
|
|
Patient satisfaction with intervention
Tijdsspanne: 6 month and 12 month for intervention patients only
|
6 month and 12 month for intervention patients only
|
|
|
CAHPS Overall Rating
Tijdsspanne: baseline, 6 month, and 12 month for intervention patients only
|
Patient satisfaction with overall care at health center
|
baseline, 6 month, and 12 month for intervention patients only
|
|
CAHPS Cultural Competency
Tijdsspanne: baseline, 6 month, and 12 month for intervention patients only
|
Patient satisfaction with cultural competency of care at health center
|
baseline, 6 month, and 12 month for intervention patients only
|
|
CAHPS Provider Communication
Tijdsspanne: baseline, 6 month, and 12 month for intervention patients only
|
Patient satisfaction with provider communication at health center
|
baseline, 6 month, and 12 month for intervention patients only
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Patient engagement
Tijdsspanne: through study completion, an average of 2 years
|
Attendance/participation in group visits, text messaging, and booster sessions
|
through study completion, an average of 2 years
|
|
Health center provider/staff preparedness
Tijdsspanne: change from pre- to post-training (from baseline to 1 month, 7 month, and 16 month)
|
Capacity, confidence, motivation, perceived benefits and barriers
|
change from pre- to post-training (from baseline to 1 month, 7 month, and 16 month)
|
|
Health center provider/staff satisfaction
Tijdsspanne: post-training (16 month)
|
Satisfaction with training, group visits, and text messaging
|
post-training (16 month)
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Onderzoekers
- Hoofdonderzoeker: Arshiya Baig, MD, MPH, University of Chicago
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
18 oktober 2018
Primaire voltooiing (Werkelijk)
15 mei 2022
Studie voltooiing (Werkelijk)
30 juni 2022
Studieregistratiedata
Eerst ingediend
21 maart 2018
Eerst ingediend dat voldeed aan de QC-criteria
27 maart 2018
Eerst geplaatst (Werkelijk)
4 april 2018
Updates van studierecords
Laatste update geplaatst (Werkelijk)
3 november 2022
Laatste update ingediend die voldeed aan QC-criteria
1 november 2022
Laatst geverifieerd
1 november 2022
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- IRB17-1385
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Diabetes mellitus type 2
-
Instituto Nacional de Ciencias Medicas y Nutricion...Actief, niet wervend
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi Demirsoy... en andere medewerkersNog niet aan het wervenType 2 diabetes | Diabetes mellitus type 2Turkije (Türkiye)
-
Endogenex, Inc.Nog niet aan het wervenDiabetes mellitus, type 2 | Suikerziekte | Diabetes mellitus type 2 | Type 2 diabetes | Type 2 diabetes
-
University of ChicagoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... en andere medewerkersWervingDiabetes mellitus type 2 (T2DM) | Diabetes noodVerenigde Staten
-
Dokuz Eylul UniversityActief, niet wervendDiabetes mellitus type 2 (T2DM) | Activering van de patiënt | Diabetes Zelfmanagement | Diabetes Mellitus (DM)Kalkoen
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationWervingDiabetes mellitus type 2 met complicatiesIndië
-
SanofiVoltooidDiabetes mellitus type 1 - Diabetes mellitus type 2Hongarije, Russische Federatie, Duitsland, Polen, Japan, Verenigde Staten, Finland
-
Endogenex, Inc.Nog niet aan het wervenDiabetes mellitus, type 2 | Suikerziekte | Type 2 diabetes | Diabetes mellitus type 2 (T2DM) | Type 2 diabetes
-
University of North Carolina, Chapel HillAmerican Heart AssociationWervingType 2 diabetes | Voeding | Diabetestype 2 | T2DM (diabetes mellitus type 2) | Diabetes mellitis | T2DM | DiabeteseducatieVerenigde Staten
-
India Diabetes Research Foundation & Dr. A. Ramachandran...Voltooid
Klinische onderzoeken op Diabetes MESSAGES Program
-
National Healthcare Group, SingaporeTan Tock Seng HospitalVoltooidDiabetespatiënten, gamification, diabeteseducatieSingapore
-
University of Texas Southwestern Medical CenterNational Institute on Minority Health and Health Disparities (NIMHD)Aanmelden op uitnodigingDiabetes mellitus, type 2 | Pre-diabetesVerenigde Staten
-
University of North Carolina, Chapel HillAmerican Diabetes AssociationWervingObesitas | Diabetes mellitus type 2 | Vreetbui syndroom | EetbuienVerenigde Staten
-
Ragae DughmoshHamad Medical Corporation; Qatar University; Qatar National Research Fund; Primary...Nog niet aan het wervenDiabetes mellitus type 2 (T2DM) | Zelfmanagement | Diabetes Zelfmanagement
-
Florida State UniversityFlorida State UniversityWerving
-
Tessa MorkJohns Hopkins Bloomberg School of Public Health; Elevance Health; AmeriGroup; Hungry...Nog niet aan het werven
-
University of Southern CaliforniaThe Leona M. and Harry B. Helmsley Charitable TrustVoltooidDiabetes mellitus type 1Verenigde Staten
-
The University of Texas at DallasUniversity of Texas Southwestern Medical Center; Congressionally Directed Medical...VoltooidTraumatische hersenschadeVerenigde Staten
-
Duke UniversityEli Lilly and Company; Bayer; Boehringer IngelheimWervingDiabetes mellitus type 2 (T2DM) | Chronische nierziekte (CKD) | Type 2 DMVerenigde Staten
-
Beth Israel Deaconess Medical CenterTiny Blue Dot FoundationNog niet aan het wervenEmotionele regulatie | Meditatie | Cognitieve herwaardering